Releasing a bit of good news, Chiron Corp. submitted a new drug application for Pulminiq inhalation solution for lung transplant patients. (BioWorld Today)

Releasing a bit of good news, Chiron Corp. submitted a new drug application for Pulminiq inhalation solution for lung transplant patients. (BioWorld Today)

AtheroGenics Inc. is discontinuing the development of one of its investigational drugs following a Phase II failure. (BioWorld Today)